Vol. 22 No. 3 (2009), Artykuły
Vol. 22 No. 3 (2009)

Hormonal replacement therapy as a breast cancer risk factor

Artykuły
Published 2009-09-30
Agnieszka Bartoszek
Department of Community Nursing, Medical University of Lublin
Katarzyna Kocka
Department of Community Nursing, Medical University of Lublin
Renata Domżał-Drzewicka
Department of Community Nursing, Medical University of Lublin
Hanna Kachaniuk
Department of Community Nursing, Medical University of Lublin
Zdzisława Szadowska-Szlachetka
Department of Integrated Medical Care, Medical University of Lublin
Marianna Charzyńska-Gula
Department of Integrated Medical Care, Medical University of Lublin

Abstract

The aim of the study was to establish a correlation between the incidence of breast cancer and the use of hormonal replacement therapy. The survey included 566 women, with a distinction between healthy women and women with breast cancer (354 and 212, respectively). The healthy women were chosen by means of the sampling method, while the women with cancer were patients after mastectomy staying at four Lublin hospitals. The method of diagnostic survey was applied, with the use of a questionnaire. The collected material underwent the statistical analysis in the form of the χ2 test. The results of the survey show that the use of hormonal replacement therapy for the period exceeding 5 years in the studied groups was statistically more frequent in the case of women after mastectomy with an elevated risk of breast cancer in the family. The percentage of women using this method of alleviating menopause symptoms increases together with age.

PDF

References

1. Antoine C., Liebens F., Carly B. et al.: Influence of HRT on prognostic factors for breast cancer: A systematic review after the Women’s Health Initiative trial. Human Reproduction, 19(3), 741, 2004.

2. Asendrych A., Deptała A.: Hormonalna terapia zastępcza w nowotworach hormonozależnych. Współczesna Onkologia, 8(2), 81, 2004.

3. Bałanda A., Gozdek N.: Postawy kobiet wobec klimakterium i hormonalnej terapii zastępczej. Pielęgniarstwo XXI wieku, 5, 79, 2003.

4. Bednaruk-Młyński E., Wójcik-Tomaszewska J., Jassem J.: Hormonalna Terapia Zastępcza, a ryzyko rozwoju raka piersi w świetle nowych doniesień. Nowotwory, 50(5), 519, 2000.

5. Beral V.: Million Women Study Collaborators. Breast cancer and hormone – replacement therapy in the Million Women Study. Lancet, 362, 419, 2003.

6. Collaborative Group on Hormonal Factors in Breast Cancer. Breast Cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiologic studies of 52.705 women with breast cancer and 108.411 women without breast cancer. Lancet, 350, 1047, 1997.

7. Dębski R.: Kontrowersje wokół hormonalnej terapii zastępczej. Przewodnik Lekarza, 4, 38, 2002.

8. Dumitrescu R. G., Cotarla I.: Understanding breast cancer risk-where do we stand in 2005?. Journal of Cellular and Molecular Medicine, 9 (1), 208, 2005.

9. Dworniak T.: Rak sutka – profilaktyka. Nowa Klinika, 10 (5/6), 535, 2003.

10. Gozdek N., Bałanda A.: Lekarze ginekolodzy i położne wobec hormonalnej terapii zastępczej. Zdrowie Publiczne, 113(3/4), 268, 2003.

11. Kanadys W. M.: Hormonalna terapia zastępcza ciągłych kontrowersji. Przegląd Menopauzalny, 2, 30, 2004.

12. Million Women Study Collaborators. Breast Cancer and hormone replacement therapy in the Million Women Study. Lancet, 362, 419, 2003.

13. Rekomendacje Zarządu Głównego PTG w sprawie stosowania Hormonalnej Terapii Zastępczej (10.07.2004). Ginekologia Polska, 9, 675, 2004.

14. Ross R. K., Paganini-Hill A., Wan P. et al.: Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin. Journal of the National Cancer Institute, 92, 328, 2000.

15. Schai rer C., Lubin J., Troisi R. et al.: Menopausal estrogen and estrogen progestin replacement therapy and breast cancer risk. Journal of the American Medical Association, 283, 485, 2000.

16. Sellers T. A., Mink P. J., Cerhan J. P.: The role of hormone replacement therapy in the risk for breast cancer and total mortality in women with a family history of breast cancer. Annals of Internal Medicine, 127(11), 973, 1997.

17. Surkont G., Wlaźlak E., Tuzin J.: Kontrowersje wokół hormonalnego leczenia zastępczego (HLZ) – praktyczne aspekty ostatnio opublikowanych wyników, badania WHI. Ginekologia Praktyczna, 11(2), 2, 2003.

18. The Women’s Health Initiative Group: Risk and benefits of estrogen plus progestin in healthy postmenopausal Women. Principal Results from the WHI Randomized Controlled Trial. Journal of the American Medical Association, 288, 321, 2002.

19. Weiss L. K., Burkman R. T., Cushing-Haugen K. L. et al.: Hormone replacement therapy regiment and breast cancer risk. Obstet. Gynecol., 100, 1148, 2002.

20. Zgliczyński S., Wiktorowicz-Dudek A.: Określenie populacji kobiet stosujących hormonalne leczenie zastępcze (HLZ). Endokrynologia Polska, 51, 271, 2000.

21. Żołnierczuk-Kieliszek D., Pacian A.: Postawy kobiet w wieku okołomenopauzalnym wobec hormonalnej terapii zastępczej. Problemy Higieny, 83, 99, 2003.

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 Unported License.

Copyright (c) 2009 Authors

Downloads

Download data is not yet available.